Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834035 · ClinicalTrials.gov registry record · Phase 1
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
A Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa, sponsored by M. Peter Marinkovich.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06834035 is a Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa that is actively recruiting participants, run by M. Peter Marinkovich. The registered enrollment target is 8 participants, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06834035, a Phase 1 study of Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa, is actively recruiting participants, sponsored by M. Peter Marinkovich.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Conditions Studied
Interventions
- BIOLOGICAL Immunoglobulin G
Study Locations (1)
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2026-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06834035
The ClinicalTrials.gov registry entry for NCT06834035 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (58% lower). The listed sponsor is M. Peter Marinkovich, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which Immunoglobulin G is the first listed.
NCT06834035 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06834035 about?
NCT06834035 is a clinical study titled "Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa". The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and H...
What is the current status of trial NCT06834035?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-08-04. Estimated completion is 2026-03-06.
What conditions does trial NCT06834035 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita.
What interventions are being tested in trial NCT06834035?
The interventions under investigation include: Immunoglobulin G (BIOLOGICAL).
Who is sponsoring clinical trial NCT06834035?
This trial is sponsored by M. Peter Marinkovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06834035 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
COMPLETED · Phase 1
-
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
COMPLETED · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
-
Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution
COMPLETED · Early Phase 1
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.